- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Alveolar pressure.
Displaying page 1 of 2.
EudraCT Number: 2015-001434-16 | Sponsor Protocol Number: 3D_CHB/collacone | Start Date*: 2016-03-30 | |||||||||||
Sponsor Name:Universitätsmedizin Greifswald, KöR | |||||||||||||
Full Title: A method for measuring volume changes of the alveolar ridge during dental implantation using 3D scanning | |||||||||||||
Medical condition: alveolar ridge atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001655-31 | Sponsor Protocol Number: AL3818-US-004 | Start Date*: 2017-12-20 | |||||||||||||||||||||
Sponsor Name:ADVENCHEN LABORATORIES, LLC | |||||||||||||||||||||||
Full Title: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma | |||||||||||||||||||||||
Medical condition: Metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018892-20 | Sponsor Protocol Number: HDZKA-2010-01 | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:Herz- & Diabeteszentrum NRW | |||||||||||||
Full Title: Pathophysiologie der Cheyne-Stokes Atmung: Senkung des pulmonalkapillären Wedge-Drucks als kausaler Therapieansatz | |||||||||||||
Medical condition: Cheyne-Stokes respiration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001863-64 | Sponsor Protocol Number: AP301-II-001 | Start Date*: 2012-07-03 |
Sponsor Name:Apeptico Forschung und Entwicklung GmbH | ||
Full Title: Proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury | ||
Medical condition: Acute Pulmonary oedema | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002867-16 | Sponsor Protocol Number: 2017-42 | Start Date*: 2017-10-05 |
Sponsor Name:Assistance Pubique Hôpitaux de Marseille | ||
Full Title: Procollagen-3 driven corticosteroids for persistent Acute Respiratory Distress Syndrome | ||
Medical condition: Acute Respiratory Distress Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005901-23 | Sponsor Protocol Number: 1552/07 | Start Date*: 2007-12-15 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Prospective,Double-Blind Randomized Clinical Trial on the Effects of Early Administration of Prolonged Methylprednisolone Therapy in early Acute Lung Injury (ALI) and Acute Respiratory Distress Syn... | |||||||||||||
Medical condition: Acute Lung Injury (ALI) - Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001360-20 | Sponsor Protocol Number: MINECRAFT | Start Date*: 2021-07-29 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: MINECRAFT Study: MINEralcorticoid receptor antagonism with CanRenone As eFfective Treatment in moderate to severe ARDS in COVID-19, a phase 2 clinical trial. | |||||||||||||
Medical condition: SARS-CoV2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001406-15 | Sponsor Protocol Number: NACATB | Start Date*: 2018-07-19 | |||||||||||
Sponsor Name:Fundació Clínic per la Recerca Biomèdica | |||||||||||||
Full Title: Adequate duration of antibiotic treatment in community acquired pneumonia categorized by pneumonia severity index (PSI) | |||||||||||||
Medical condition: Community Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002403-13 | Sponsor Protocol Number: Ularitide-1502 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:PDL BioPharma Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure | |||||||||||||
Medical condition: Acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001939-27 | Sponsor Protocol Number: SystABSinus01 | Start Date*: 2021-02-25 |
Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Zahn-, Mund- und Kieferheilkunde | ||
Full Title: The effect of systemic antibiotics on post-surgical complications and patient-centered outcomes in patients undergoing implant surgery with guided bone regeneration and simultaneous sinus floor ele... | ||
Medical condition: patients undergoing oral implant therapy with simultaneous lateral sinus floor elevation and guided bone regeneration (GBR) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001885-40 | Sponsor Protocol Number: Syst-AB+Sinus | Start Date*: 2022-02-24 |
Sponsor Name:Universidad Complutense de Madrid | ||
Full Title: The effect of systemic antibiotics on post-surgical complications and paitent-centered outomes in patients undergoing implant surgery with the guided bone regeneration and simultaneous sinus floor ... | ||
Medical condition: The medical condition that the patients have in this trial is edentulism in a posterior maxillary quadrant of the mouth with a sinus pneumatisation/ decreased crestal bone heigh defect requiring a... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001550-22 | Sponsor Protocol Number: AMY-101_SAVE | Start Date*: 2020-11-04 |
Sponsor Name:Amyndas Pharmaceuticals S.A. | ||
Full Title: A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. | ||
Medical condition: Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 infection. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001238-32 | Sponsor Protocol Number: ADVL1622 | Start Date*: 2019-09-26 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation | ||
Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ||
Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-002494-28 | Sponsor Protocol Number: 6 | Start Date*: 2023-05-18 | |||||||||||
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red, (CIBER) | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
Medical condition: Intensive Care Unit patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004408-32 | Sponsor Protocol Number: AMY-101_ITHACA | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:Amyndas Pharmaceuticals S.A. | |||||||||||||
Full Title: ITHACA: A phase 2, randomized, single-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of the complement C3 inhibitor, AMY-101, in COVID-19 patients with acute respirato... | |||||||||||||
Medical condition: Severe COVID-19, with Acute Respiratory Distress Syndrome (ARDS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002287-11 | Sponsor Protocol Number: BAY1021189/15371 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) DE (Completed) ES (Completed) NL (Completed) HU (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002288-25 | Sponsor Protocol Number: BAY1021189/15829 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003519-40 | Sponsor Protocol Number: 03-CL-1202 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A MULTINATIONAL, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF LUCINACTANT FOR INHALATION IN PRETERM NEONATES 26 TO 32 WEEKS GESTATIONAL AGE WITH RESPIRATOR... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) IE (Completed) NL (Completed) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
